Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1

• Main Authors: Anastasie M. Dunn-Pirio, Elizabeth Howell, Roger E. McLendon, Katherine B. Peters
• Format: Article
• Language: English
• Published: Karger Publishers 2016-10-01
• Series: Case Reports in Oncology
• Subjects: Spinal cord tumor; Astrocytoma; Pilomyxoid astrocytoma; Neurofibromatosis type 1; Carboplatin
• Online Access: http://www.karger.com/Article/FullText/449406

Introduction: Pilomyxoid astrocytoma (PMA) is a rare and more aggressive variant of pilocytic astrocytoma, which usually affects young children and is most often located in the hypothalamic/chiasmatic region. The association of PMA with underlying genetic disorders is not well known. Methods: We identified a 23-year-old woman with a PMA of the spinal cord who was simultaneously diagnosed with neurofibromatosis type 1. Diagnosis of neurofibromatosis type 1 was made clinically and confirmed with genetic testing that revealed a heterozygous one-amino-acid deletion (c.2970–2972 delAAT) in exon 17 of the NF1 gene, which is correlated with a milder phenotype. The patient underwent a partial surgical resection of the spinal cord tumor followed by adjuvant carboplatin 560 mg/m2 every 4 weeks. Radiation was avoided due to risks associated with neurofibromatosis type 1. Results: At the 11-month follow-up, the patient maintained a partial radiographic response as well as complete resolution of her neurologic deficits. Conclusion: To our knowledge, this is the first reported case of an adult patient with neurofibromatosis type 1 and a spinal cord PMA. Single-agent carboplatin was effective and well-tolerated.